Phentermine and topiramate extended release (Qsymia™): first global approval

Drugs. 2012 Oct 22;72(15):2033-42. doi: 10.2165/11640860-000000000-00000.


Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed to produce weight loss by decreasing appetite and increasing satiety. The product is also in clinical development for sleep apnoea syndrome and type 2 diabetes mellitus. This article summarizes the milestones in the development of phentermine/topiramate ER leading to this first approval for obesity.

MeSH terms

  • Anti-Obesity Agents / administration & dosage*
  • Appetite Depressants / administration & dosage*
  • Clinical Trials as Topic
  • Delayed-Action Preparations
  • Fructose / administration & dosage
  • Fructose / analogs & derivatives*
  • Humans
  • Obesity / drug therapy
  • Phentermine / administration & dosage*
  • Randomized Controlled Trials as Topic
  • Topiramate


  • Anti-Obesity Agents
  • Appetite Depressants
  • Delayed-Action Preparations
  • Topiramate
  • Fructose
  • Phentermine